INBX
SHORT CANDIDATEMeanRevComposite
27.70
Technical
32.00
Fundamental
26.30
Rank
—
Price
90.50
Hurst
0.01
As of
Oct 16, 2026
Daily
Inhibrx Biosciences, Inc.
HealthcareBiotechnologyInhibrx Biosciences is a clinical-stage biopharmaceutical company developing biologic drugs to treat serious illnesses. The company's pipeline includes INBRX-109, a tetravalent candidate in early testing that targets death-receptor 5 for chondrosarcoma, and INBRX-106, a hexavalent antibody-based candidate targeting OX40 for various metastatic cancers including lung cancer, melanoma, gastric cancer, and renal cell carcinoma. The company was established in 2024 and is located in La Jolla, California.
Market cap
$1.1B
P/E (trailing)
—
P/E (forward)
-8.19
PEG ratio
—
Dividend yield
0.00%
Beta
3.82
52w range
57.30 – 155.29
Return on equity
-1773.60%
Profit margin
0.00%
Revenue growth
—
Earnings growth
—
Price history
1Y: 71.78 (-12.1%) · range 58.39–141.84
Cycle position
18/ 100 cycle scoreENTRY ZONE
ENTRYAPPROACHMID-BULLNEAR-TOPEXIT
entry readiness 89 · STRONG SETUP · exit proximity 0
Conviction
59/ 100 · maturity 29%
VScore.1613
Buildup.2870
EMA entry setup.3589
Fundamentals.2126
Volume profile
POC
93.13
Price vs POC
-22.9%
Overhead supply
99%
Runway
+27.9%
Value area 86.06–110.46 · 99% of 120d volume overhead · heavy supply
Contributing sources
| Source | Score | Last seen |
|---|---|---|
| insider-activity | 0.740 | Oct 16, 2026 |
Forward returns
| Horizon | Return | MFE | State |
|---|---|---|---|
| 20d | -4.90% | -1.11% | 2/20d |
| 40d | -4.90% | -1.11% | 2/40d |